PDS Bio (PDSB) Stock Forecast, Price Target & Predictions
PDSB Stock Forecast
PDS Bio stock forecast is as follows: an average price target of $9.00 (represents a 343.35% upside from PDSB’s last price of $2.03) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
PDSB Price Target
The average price target for PDS Bio (PDSB) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $9.00. This represents a potential 343.35% upside from PDSB's last price of $2.03.
PDSB Analyst Ratings
According to 3 Wall Street analysts, PDS Bio's rating consensus is 'Buy'. The analyst rating breakdown for PDSB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PDS Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 12, 2024 | Mayank Mamtani | B.Riley Financial | $9.00 | $2.76 | 226.09% | 343.35% |
| Mar 28, 2024 | Mayank Mamtani | B.Riley Financial | $11.00 | $3.85 | 185.71% | 441.87% |
The latest PDS Bio stock forecast, released on Jun 12, 2024 by Mayank Mamtani from B.Riley Financial, set a price target of $9.00, which represents a 226.09% increase from the stock price at the time of the forecast ($2.76), and a 343.35% increase from PDSB last price ($2.03).
PDS Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $2.03 | $2.03 | $2.03 |
| Upside/Downside | -100.00% | -100.00% | 392.61% |
In the current month, the average price target of PDS Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PDS Bio's last price of $2.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 20, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Mar 28, 2024 | Alliance Global Partners | Buy | Buy | Hold |
| Nov 15, 2022 | Chardan Capital | Buy | Buy | Hold |
| May 13, 2022 | Alliance Global Partners | Buy | Buy | Hold |
PDS Bio's last stock rating was published by H.C. Wainwright on Oct 03, 2024. The company gave PDSB a "Buy" rating, the same as its previous rate.
PDS Bio Financial Forecast
PDS Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PDSB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PDS Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PDSB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PDS Bio's previous annual EBITDA (undefined) of $NaN.
PDS Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-12.70M | $-12.33M | $-12.33M | $-12.15M | $-11.23M | $-10.92M | $-11.99M |
| High Forecast | $-12.70M | $-12.33M | $-12.33M | $-12.15M | $-10.10M | $-10.92M | $-11.99M |
| Low Forecast | $-12.70M | $-12.33M | $-12.33M | $-12.15M | $-12.72M | $-10.92M | $-11.99M |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PDSB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PDS Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
PDS Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PDSB last annual SG&A of $NaN (undefined).
PDS Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.34 | $-0.34 | $-0.34 | $-0.33 | $-0.30 | $-0.30 | $-0.33 |
| High Forecast | $-0.34 | $-0.34 | $-0.34 | $-0.33 | $-0.27 | $-0.30 | $-0.33 |
| Low Forecast | $-0.34 | $-0.34 | $-0.34 | $-0.33 | $-0.35 | $-0.30 | $-0.33 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PDS Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PDSB previous annual EPS of $NaN (undefined).
PDS Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.58 | $9.00 | 1451.72% | Buy |
| XFOR | X4 Pharmaceuticals | $0.34 | $3.67 | 979.41% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| PDSB | PDS Bio | $2.03 | $9.00 | 343.35% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| TERN | Terns Pharmaceuticals | $5.60 | $14.25 | 154.46% | Buy |
| MREO | Mereo BioPharma Group | $3.58 | $6.75 | 88.55% | Buy |
| HOOK | HOOKIPA Pharma | $2.72 | $3.00 | 10.29% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |